Dual-action. Up to 22% body weight lost.
Tirzepatide — the active ingredient in Mounjaro® and Zepbound® — activates two hormone pathways simultaneously: GLP-1 and GIP. The result is the most significant weight loss ever recorded in a clinical trial for an approved medication.
Tirzepatide targets two hunger hormones. Semaglutide targets one.
GLP-1 tells your brain you're full. GIP enhances insulin sensitivity and fat metabolism. Together, they produce weight loss results that exceed any single-mechanism medication ever studied.
For patients with significant obesity who want the most clinically potent option available, tirzepatide's dual mechanism produces up to 22% body weight loss in clinical trials — exceeding the approximately 15% seen with semaglutide in comparable populations. FDA-approved as Zepbound® for chronic weight management in adults with obesity or overweight with at least one weight-related condition.
Tirzepatide is FDA-approved as Mounjaro® for type 2 diabetes — and in clinical trials produced HbA1c reductions greater than any previously approved diabetes medication. The GIP component enhances insulin sensitivity directly, making tirzepatide particularly effective for patients whose weight is driven by insulin resistance and metabolic dysfunction.
Where semaglutide's single GLP-1 mechanism has not produced sufficient appetite control, tirzepatide's dual activation of GLP-1 and GIP receptors produces a more profound and durable satiety signal. For patients who remain persistently hungry on semaglutide, tirzepatide is the logical clinical escalation.
A notable finding in tirzepatide trials is a higher proportion of fat mass loss relative to lean mass loss compared to semaglutide. For patients concerned about muscle loss alongside weight reduction — particularly active patients and older adults — tirzepatide's GIP component appears to provide a metabolic advantage in preserving lean body composition.
Beyond weight, tirzepatide improves blood pressure, triglycerides, HDL cholesterol, and inflammatory markers — the full cardiovascular risk factor profile associated with obesity and metabolic syndrome. Ongoing cardiovascular outcomes trials (SURMOUNT-MMO) are expected to confirm mortality and event reduction benefits comparable to or exceeding semaglutide's SELECT trial results.
Tirzepatide has demonstrated significant reductions in liver fat in patients with NAFLD — a condition affecting a large proportion of overweight and obese adults. Weight loss itself improves NAFLD, but tirzepatide's metabolic effects on hepatic fat metabolism appear to produce benefits beyond what weight loss alone explains.
More than one-third of Americans live with obesity. Tirzepatide offers the most effective medical weight loss available today.
Clinically supervised at Iuventus Medical Center — weekly injections, individualized protocol, diet and exercise guidance, and ongoing monitoring. No starvation. No one-size-fits-all program. A medical approach that produces long-lasting results.
Two hormones. One injection. Double the effect.
Tirzepatide is a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist — the first medication of its class. GLP-1, as in semaglutide, signals satiety, stimulates insulin, and slows gastric emptying. GIP — the additional pathway tirzepatide activates — enhances insulin sensitivity, promotes fat metabolism, and acts on the brain's reward system in ways that further reduce food-seeking behavior. The combination of both pathways produces a synergistic effect that exceeds what either mechanism alone can achieve.
The SURMOUNT-1 clinical trial — the largest weight loss medication trial ever conducted — showed participants receiving the highest dose of tirzepatide (15mg weekly) lost an average of 22.5% of their body weight over 72 weeks. More than half of participants lost 20% or more. These are results previously associated only with bariatric surgery.
At Iuventus, tirzepatide is prescribed as part of a comprehensive clinically supervised program — weekly injections alongside individualized meal and workout plans, physician monitoring throughout, and a long-term maintenance strategy. More than one-third of Americans live with obesity. Many don't achieve health benefits because they lack the right medical support. Our program provides that support.
GLP-1: suppresses appetite, stimulates insulin, slows gastric emptying — the same mechanism as semaglutide. GIP: enhances insulin sensitivity, promotes fat cell metabolism, acts on the brain's reward and satiety pathways through a different receptor. The combination is synergistic — each pathway amplifies the other's effect on weight, blood sugar, and metabolic health.
Tirzepatide vs. Semaglutide — dual vs. single mechanism.
Both are weekly injectable FDA-approved weight loss medications. Tirzepatide's dual mechanism produces greater weight loss on average. Your physician will recommend based on your goals, history, and tolerance.
| Feature | Tirzepatide ★ | Semaglutide |
|---|---|---|
| Brand names | Mounjaro® / Zepbound® | Ozempic® / Wegovy® |
| Mechanism | Dual GLP-1 + GIP agonist | GLP-1 receptor agonist only |
| FDA-approved (wt loss) | ✓ Zepbound® 2023 | ✓ Wegovy® 2021 |
| Avg. weight loss | Up to 22% body weight | 10–20% body weight |
| HbA1c reduction | Greater than any prior med | Significant reduction |
| Lean mass preservation | Favorable — GIP effect | Standard for GLP-1 class |
| Cardiovascular data | Ongoing — expected strong | ✓ SELECT trial 20% CV risk reduction |
| Best for | Maximum weight loss, T2D, insulin resistance | Proven first-line, strong CV data |
The most effective weight loss medication ever studied.
The SURMOUNT-1 trial results exceeded expectations for any non-surgical weight loss intervention. Tirzepatide's dual-mechanism approach represents a fundamental advance over single-agonist GLP-1 medications.
From overweight to your best version.
A certified medical professional evaluates your health condition, food choices, physical activity routine, and weight history. We review contraindications and determine whether tirzepatide or semaglutide is the right choice for your goals.
Tirzepatide is injected subcutaneously once per week. Dose is titrated from 2.5mg upward over 20 weeks to the optimal therapeutic dose, minimizing GI side effects during adjustment.
Medical specialists prepare custom programs tailored to your weight loss goals and current health condition. We teach you how to make the right food choices without starvation — and build the habits that make results last.
Regular check-ins throughout. Weight, metabolic markers, and side effects monitored. Long-lasting health and aesthetic results visible in weeks — with new habits incorporated into your lifestyle for results that don't reverse.
Medicine that
gets you.
Tirzepatide is the most advanced weight loss medication available. The program around it determines whether results are sustained. We provide both.
The Most Powerful Approved Option
Tirzepatide's SURMOUNT-1 results are unprecedented for an approved medication. For patients who need maximum weight loss or haven't achieved sufficient results on semaglutide, tirzepatide is the clinical escalation that the evidence supports.
Clinically Supervised Throughout
At Iuventus our weight loss programs offer a clinically supervised approach to sustainable health. We don't prescribe and disappear — physician oversight at every stage of the program.
Forming the Right Habits, Not Just Losing Weight
Medical weight management helps develop and maintain good habits with effort and time, keeping you accountable. The medication makes this sustainable. The program makes it lasting.
Affordable & Accessible in Las Vegas
After a thorough assessment, we pick the program right for you. We won't make you starve or stop enjoying your life. Our goal is sustainable health — and we provide the medical framework to get there.
Results that match
the clinical trials.
Everything you
want to know.
Decide to become
a better version of you today.
A free consultation and thorough assessment. We pick the program that is right for you — no starvation, no one-size approach. Long-lasting health and aesthetic results. Iuventus Medical Center Las Vegas.